Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib In Treatment Of Metastatic Castrate Refractory Prostate Cancer
26/06/2023 17:15
June 26 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN
PATENT
COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE
REFRACTORY PROSTATE CANCER (MCRPC)
* THIS NEW EUROPEAN PATENT PROVIDES INTELLECTUAL PROPERTY
PROTECTION FOR MASITINIB IN TREATMENT OF MCRPC UNTIL 2042
Source text for Eikon: ID:nGNE7Lz8lt
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041